ArticleEuropean radiology2026
Multiparametric MRI with pea pod sign and muscularis propria striped enhancement improves T2 vs T3a-b rectal cancer staging accuracy.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the diagnostic value of a multi-parametric MRI model integrating functional (DWI/DCE) and morphological (T2WI) biomarkers for differentiating T2-stage from T3a-b-stage rectal lesions. MATERIALS AND
methods532 rectal cancer patients (T2-stage, n = 319; T3a-b-stage, n = 213) were enrolled in this study. Two radiologists independently evaluated tumor characteristics (status of muscularis propria (SMP), pea pod sign (PPS), depression sign (DS), muscularis propria striped enhancement (MPSE), statue of mesorectal signal (SMS), lymph node involvement, tumor location, and size) at MRI. The associations of clinical and imaging characteristics with stage T2 or T3a-b tumors were assessed, b values were calculated, and predictive models were built for distinguishing T2-stage from T3a-b-stage lesions.
resultsData from 532 patients (mean age, 63 years ± 11 [standard deviation]; 343 men) were evaluated. PPS (b = 4.04; 95% CI: 2.49, 6.54), DS (b = 5.02; 95% CI: 1.91, 13.16), MPSE (b = 8.99; 95% CI: 5.46, 14.79), and distance from the tumor to the anal verge (DTA) (b = 0.99; 95% CI: 0.98, 1.00) were independent factors differentiating T2-stage tumors from T3a-b lesions. The area under the curve (AUC) was 0.85 (95% CI: 0.81-0.88). The nomogram achieved a bootstrapped concordance index of 0.84 and demonstrated good calibration.
conclusionsThe multi-parametric MRI model integrating functional (DWI/DCE) and morphological (T2WI) biomarkers showed potential clinical utility in distinguishing T2-stage from T3a-b-stage rectal lesions. Moreover, PPS and MPSE are more accurate features than SMP. KEY POINTS: Question MRI can improve differentiation between T2 and early T3a-b rectal cancer stages to reduce current overstaging errors and guide optimal treatment decisions. Findings A multi-parametric MRI model integrating pea pod sign and muscularis propria striped enhancement outperforms conventional T2-weighted assessments. Clinical relevance Accurate T2 vs T3a-b distinction prevents unnecessary neoadjuvant chemoradiotherapy for T2 patients while ensuring timely therapy for T3a-b, optimizing treatment outcomes and reducing overtreatment toxicity.
Indexed as
Identifiers
41307661What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.